Literature DB >> 1311018

Structural analysis of a mouse mammary tumor virus superantigen.

Y Choi1, P Marrack, J W Kappler.   

Abstract

It has recently been shown that the minor lymphocyte stimulating-like products expressed by some mice are actually encoded by open reading frames in the 3' long terminal repeats of mouse mammary tumor viruses. These products act as viral superantigens (vSAGs). That is, they stimulate most T cells bearing particular V beta s almost regardless of the rest of the variable components of the T cell receptors expressed by those cells. To find out more about the structure of these vSAGs, a set of truncated vSAG genes was used in transfection and in vitro translation experiments to show that the functional vSAG is a type II integral membrane protein with a large glycosylated extracellular COOH-terminal domain and a small, nonessential, intracellular NH2-terminal cytoplasmic domain. These results are consistent with the fact that the vSAGs must be expressed on the cell surface in order to interact with T cells and class II major histocompatibility complex proteins. They also account for the finding that much of the V beta specificity of the vSAGs is controlled by amino acids at the COOH-terminal end of the vSAG proteins, amino acids that will be extracellular in type II proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311018      PMCID: PMC2119154          DOI: 10.1084/jem.175.3.847

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  T lymphocyte responses to Mls locus antigens involve recognition of H-2 I region gene products.

Authors:  A B Peck; C A Janeway; H Wigzell
Journal:  Nature       Date:  1977-04-28       Impact factor: 49.962

2.  Identification of the region of T cell receptor beta chain that interacts with the self-superantigen MIs-1a.

Authors:  A M Pullen; T Wade; P Marrack; J W Kappler
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

3.  T cell recognition of Mlsc. I. Influence of MHC gene products in Mlsc-specific T cell recognition.

Authors:  R Abe; R J Hodes
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

Review 4.  Immunogenetic and biological aspects of in vitro lymphocyte allotransformation (MLR) in the mouse.

Authors:  H Festenstein
Journal:  Transplant Rev       Date:  1973

5.  Relationship of B cell Fc receptors to T cell recognition of Mls antigen.

Authors:  J F Nicolas; D Wegmann; P Lebrun; D Kaiserlian; J Tovey; A L Glasebrook
Journal:  Eur J Immunol       Date:  1987-11       Impact factor: 5.532

6.  Further evidence for the protein coding potential of the mouse mammary tumor virus long terminal repeat: nucleotide sequence of an endogenous proviral long terminal repeat.

Authors:  L A Donehower; B Fleurdelys; G L Hager
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

7.  Regulatory and coding potential of the mouse mammary tumor virus long terminal redundancy.

Authors:  L A Donehower; A L Huang; G L Hager
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

8.  A tripartite structure of the signals that determine protein insertion into the endoplasmic reticulum membrane.

Authors:  M T Haeuptle; N Flint; N M Gough; B Dobberstein
Journal:  J Cell Biol       Date:  1989-04       Impact factor: 10.539

9.  The open reading frames in the 3' long terminal repeats of several mouse mammary tumor virus integrants encode V beta 3-specific superantigens.

Authors:  A M Pullen; Y Choi; E Kushnir; J Kappler; P Marrack
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

10.  Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition.

Authors:  J W Kappler; B Skidmore; J White; P Marrack
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  27 in total

1.  Alternative proteolytic processing of mouse mammary tumor virus superantigens.

Authors:  F Denis; N H Shoukry; M Delcourt; J Thibodeau; N Labrecque; H McGrath; J S Munzer; N G Seidah; R P Sékaly
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Tcrb-V12-specific superantigens encoded by mouse mammary tumor proviruses.

Authors:  K Tomonari
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

Review 3.  Virus-encoded superantigens.

Authors:  B T Huber; P N Hsu; N Sutkowski
Journal:  Microbiol Rev       Date:  1996-09

4.  Mutational and functional analysis of the C-terminal region of the C3H mouse mammary tumor virus superantigen.

Authors:  T J Wrona; M Lozano; A A Binhazim; J P Dudley
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen.

Authors:  C Krummenacher; H Diggelmann; H Acha-Orbea
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 6.  Bacterial pyrogenic exotoxins as superantigens.

Authors:  M Kotb
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  A novel V beta 2-specific endogenous mouse mammary tumor virus which is capable of producing a milk-borne exogenous virus.

Authors:  N Niimi; W Wajjwalku; Y Ando; N Nakamura; M Ueda; Y Yoshikai
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Coexpression of exogenous and endogenous mouse mammary tumor virus RNA in vivo results in viral recombination and broadens the virus host range.

Authors:  T V Golovkina; A B Jaffe; S R Ross
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Mouse mammary tumor virus superantigen expression in B cells is regulated by a central enhancer within the pol gene.

Authors:  F U Reuss; J M Coffin
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Mouse mammary tumor virus-induced tumorigenesis in sag transgenic mice: a laboratory model of natural selection.

Authors:  T V Golovkina; J A Prescott; S R Ross
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.